医学
银屑病
药品
重症监护医学
安全概况
不利影响
药理学
皮肤病科
作者
Luca Potestio,Nello Tommasino,Giuseppe Lauletta,Federica Feo,Angelo Ruggiero,Fabrizio Martora,Antonio Portarapillo,Luigi Guerriero,Matteo Megna
标识
DOI:10.1080/14740338.2024.2351462
摘要
Deucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approaches required for the treatment of this disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI